Gastrointestinal Malignancy
Conditions
Interventions
Intervention Group:Mongolian Medicine Mind-Body Interaction Therapy: Group interaction model, 15-20 people per group, once daily for 3 hours, continuous for 28 days. Includes: Opening preparation (mus
Control Group:Standard oncology treatment and nursing care: including standardized chemotherapy regimens (based on pathology and staging, such as cmFOLFOXIRI), routine nursing (chemotherapy education,
Sponsors
Inner Mongolia International Mongolian Medical Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with gastrointestinal malignancies such as gastric cancer and colorectal cancer through pathological or imaging examinations; 2. For patients undergoing chemotherapy or within no more than one month after the end of chemotherapy, the chemotherapy regimen should follow the principles of standardized treatment for gastrointestinal malignancies and can be adjusted according to the patient's pathological type and stage (for example, for colorectal cancer, the "Chinese standard" chemotherapy regimens such as cmFOLFOXIRI can be referred to). 3. Age: 18 to 70 years old, gender not limited; 4. Primary school education or above, with basic comprehension and communication skills, capable of cooperating to complete scale assessment and intervention measures; 5. The Karlsberg Performance Status Score (KPS) is >=60 points, and the individual has a certain level of physical activity ability. 6. Expected survival period >=6 months; 7. Voluntarily participate in this study, sign the informed consent form, and be willing to cooperate to complete the entire intervention and follow-up process.
Exclusion criteria
Exclusion criteria: 1. Those with a history of cognitive impairment, mental illness (such as schizophrenia, bipolar disorder, etc.) or severe neurological deficits; 2. Those with severe functional disorders of vital organs such as the heart, liver and kidneys, or other serious chronic diseases (such as severe diabetes, hypertensive crisis, etc.), and who cannot tolerate intervention; 3. Pregnant or lactating women; 4. Those who participate in other psychological intervention trials or anti-tumor clinical trials simultaneously; 5. Those who have a clear resistance to the Mongolian medicine mind-body interaction therapy or are unable to cooperate to complete the intervention process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mood Status (Depression and Anxiety); | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life;Physical Function Status;Immune Function (T Lymphocyte Subsets);Inflammatory Status (Serum CRP, IL-6, IL-10);Safety Outcomes (including Adverse Events and Reasons for Dropouts/Loss to Follow-up); | — |
Countries
China
Contacts
Public ContactNa Risu
Inner Mongolia International Mongolian Medical Hospital
Outcome results
None listed